(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Wonderful Getaway destination - 2Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- 3The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- 4Vote in favor of your Favored sort of footwear
- 5Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Figure out How to Put resources into Lab Precious stones
- Vote in favor of Your #1 Climbing boots Now
- The Best Design Bloggers for Style Motivation
- Elite Execution Wall televisions for Film Darlings
- Why are malnutrition deaths soaring in America?
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Enormous Credit And All that You Really want To Be aware
